Missouri is currently home to 1891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
NCT04819841
Recruiting
This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.
Gender:
ALL
Ages:
Between 12 years and 40 years
Trial Updated:
06/12/2025
Locations: Washington University, St. Louis, Missouri
Conditions: Sickle Cell Disease
Register for Updates
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462
Recruiting
The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A2301 clinical trials. The open-label design of the current study is appropriate to provide study participants the opportunity to receive treatment with iptacopan until marketing authorizations are received and the drug product becomes commercially available while enabling collection of long-term safet... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/12/2025
Locations: Clinical Research Consultants LLC, Kansas City, Missouri
Conditions: Primary IgA Nephropathy
Register for Updates
Cabozantinib in High Grade Neuroendocrine Neoplasms
NCT04412629
Recruiting
High grade neuroendocrine neoplasm patients are treated with platinum doublets such as carboplatin and etoposide mimicking the current guidelines for small cell lung cancer (SCLC). Unfortunately, recurrences are common and most patients with metastatic disease succumb to it within a year. There is no extensive literature or consensus on second- or third-line options (which include FOLFOX, FOLFIRI, capecitabine and temozolomide, taxanes or immunotherapy) and there is urgent need for better regime... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: High Grade Neuroendocrine Neoplasms
Register for Updates
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
NCT04373317
Recruiting
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions). Hallucinations or delusions, together called psychosis, occur in u... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/12/2025
Locations: St. Louis VA Medical Center John Cochran Division, St. Louis, MO, Saint Louis, Missouri
Conditions: Parkinson's Disease Psychosis
Register for Updates
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
NCT03615235
Recruiting
The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from ki... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/12/2025
Locations: Saint Louis University Center for Transplantation, Saint Louis, Missouri
Conditions: Kidney Diseases, Kidney Failure, Kidney Disease, Chronic
Register for Updates
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
NCT06625411
Recruiting
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/11/2025
Locations: University Health, Kansas City, Missouri
Conditions: Thyroid Eye Disease
Register for Updates
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085
Recruiting
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
Gender:
ALL
Ages:
Between 29 days and 17 years
Trial Updated:
06/11/2025
Locations: Washington University-Pediatric Cardiology/ St. Louis Children's Hospital ( Site 0006), Saint Louis, Missouri
Conditions: Heart Failure, Left Ventricular Systolic Dysfunction
Register for Updates
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106
Recruiting
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Gender:
ALL
Ages:
Between 35 years and 85 years
Trial Updated:
06/11/2025
Locations: The Washington University, Saint Louis, Missouri
Conditions: Alzheimer's Disease, Prodromal Alzheimer's Disease, Amyloid Plaque, Beta-Amyloid, Alzheimer's Disease in Down Syndrome
Register for Updates
A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
NCT05094336
Recruiting
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of AMG 193 in adult participants with metastatic or locally advanced MTAP-nul... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/11/2025
Locations: Washington University, Saint Louis, Missouri
Conditions: Advanced MTAP-null Solid Tumors
Register for Updates
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797
Recruiting
The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Kansas City Research Institute, Kansas City, Missouri
Conditions: Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms
Register for Updates
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07011667
Recruiting
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more li... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Amicis Centers of Clinical Research, Saint Louis, Missouri
Conditions: Obesity
Register for Updates
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
NCT06745063
Recruiting
The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.
Gender:
ALL
Ages:
Between 30 years and 60 years
Trial Updated:
06/10/2025
Locations: Harry S. Truman Memorial, Columbia, MO, Columbia, Missouri
Conditions: Obesity, Vascular Health
Register for Updates